DrugPatentWatch Database Preview
Hydrocortisone sodium succinate - Generic Drug Details
What are the generic sources for hydrocortisone sodium succinate and what is the scope of hydrocortisone sodium succinate freedom to operate?
Hydrocortisone sodium succinate
is the generic ingredient in three branded drugs marketed by Abbott, Hospira, Abraxis Pharm, Baxter Hlthcare, Intl Medication, Watson Labs, and Pharmacia And Upjohn, and is included in twenty-five NDAs. Additional information is available in the individual branded drug profile pages.There are sixty-five drug master file entries for hydrocortisone sodium succinate. Three suppliers are listed for this compound.
Summary for hydrocortisone sodium succinate
| US Patents: | 0 |
| Tradenames: | 3 |
| Applicants: | 7 |
| NDAs: | 25 |
| Drug Master File Entries: | 65 |
| Suppliers / Packagers: | 3 |
| Bulk Api Vendors: | 67 |
| Clinical Trials: | 8 |
| Patent Applications: | 2,039 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | hydrocortisone sodium succinate at DailyMed |
Pharmacology for hydrocortisone sodium succinate
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Synonyms for hydrocortisone sodium succinate
| (11-beta)-21-(3-Carboxy-1-oxopropoxy)-11,17-dihydroxypreg-4-ene-3,20-dione |
| 11|A,17|A,21-Trihydroxy-4-pregnene-3,20-dione 21-hemisuccinate |
| 11|A,17|A,21-Trihydroxy-4-pregnene-3,20-dione 21-hemisuccinate sodium salt |
| 11beta,17,21-Trihydroxypregn-4-ene-3,20-dione 21-(hydrogensuccinate) |
| 11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione 21-hemisuccinate sodium salt |
| 11beta,17alpha,21-trihydroxypregn-4-ene-3,20-dione 21-succinate |
| 125-04-2 |
| 125-04-2 (hydrochloride salt) |
| 125H042 |
| 2203-97-6 |
| 2203-97-6 (Parent) |
| 3-{[2-((1S,10S,11S,15S,17S,2R,14R)-14,17-dihydroxy-2,15-dimethyl-5-oxotetracyc lo[8.7.0.0<2,7>.0<11,15>]heptadec-6-en-14-yl)-2-oxoethyl]oxycarbonyl}propanoic acid |
| 3-{[2-((1S,10S,11S,15S,17S,2R,14R)-14,17-dihydroxy-2,15-dimethyl-5-oxotetracyc lo[8.7.0.0<2,7>.0<11,15>]heptadec-6-en-14-yl)-2-oxoethyl]oxycarbonyl}propanoic acid, sodium salt |
| 4-((11,17-Dihydroxy-3,20-dioxopregn-4-en-21-yl)oxy)-4-oxobutanoic acid |
| 4-(2-((8S,9S,10R,11S,13S,14S,17R)-11,17-Dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethoxy)-4-oxobutanoic acid |
| 4-[2-[(8S,9S,10R,11S,13S,14S,17R)-10,13-dimethyl-11,17-bis(oxidanyl)-3-oxidanylidene-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxidanylidene-ethoxy]-4-oxidanylidene-butanoic acid |
| 4-[2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxo-ethoxy]-4-oxo-butanoic acid |
| 4-[2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-4-oxobutanoic acid |
| 4-{2-[(1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-14-yl]-2-oxoethoxy}-4-oxobutanoic acid |
| 4-{2-[(1S,2R,10S,11S,14R,15S,17S)-14,17-DIHYDROXY-2,15-DIMETHYL-5-OXOTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADEC-6-EN-14-YL]-2-OXOETHOXY}-4-OXOBUTANOIC ACID |
| 50LQB69S1Z |
| A-hydroCort |
| A-hydrocort (TN) |
| A815861 |
| Aacicortisol |
| AC-6828 |
| AC1L28CF |
| Aftasome |
| AJ-47999 |
| AK307048 |
| AKOS015969742 |
| AKOS024386295 |
| AKOS024386298 |
| AN-9607 |
| API0002945 |
| Arcocort |
| BDBM50016931 |
| Bio-0653 |
| Buccalsone |
| C-22617 |
| C08178 |
| C12888 |
| C25H33NaO8 |
| C25H34O8 |
| Ca>> inverted question markEmicroAEE 21- degrees ecuceEao yen |
| CAS-125-04-2 |
| CC-29422 |
| CHEBI:31677 |
| CHEBI:5782 |
| CHEMBL1200495 |
| CHEMBL977 |
| Corlan |
| Cortisol 21-(sodium succinate) |
| Cortisol 21-hemisuccinate |
| Cortisol 21-hemisuccinate sodium |
| CORTISOL 21-HEMISUCCINATE SODIUM SALT |
| Cortisol 21-sodium succinate |
| Cortisol hemisuccinate |
| Cortisol hemisuccinate sodium salt |
| Cortisol sodium hemisuccinate |
| Cortisol sodium succinate |
| Cortisol succinate |
| Cortisol, 21-(hydrogen succinate) |
| Cortisol, 21-(hydrogen succinate), monosodium salt (8CI) |
| Cortisol, hydrogen succinate |
| Cortisol, monosodium salt |
| CORTISOL, SUCCINATE, SODIUM SALT |
| Cortop |
| CPD000058328 |
| CTK8G0222 |
| D00978 |
| D01442 |
| DSSTox_CID_28932 |
| DSSTox_GSID_49006 |
| DSSTox_RID_83198 |
| DTXSID2049006 |
| DTXSID40872905 |
| EF-Cortelan soluble |
| EINECS 204-725-5 |
| EINECS 218-612-3 |
| Emi-Corlin |
| EN300-55845 |
| EU-0100623 |
| Flebocortid |
| Flebocortid [inj.] |
| FT-0627127 |
| GS-6198 |
| H 2270 |
| Hidrokortizon |
| HMS2234H22 |
| HMS2235G13 |
| HMS3259A14 |
| Hycorace |
| Hydro-Adreson aquosum |
| Hydrocortisone 21-(hydrogen succinate) |
| Hydrocortisone 21-(sodium succinate) |
| Hydrocortisone 21-hemisuccinate |
| Hydrocortisone 21-hemisuccinate sodium |
| Hydrocortisone 21-hemisuccinate sodium salt |
| Hydrocortisone 21-hemisuccinate sodium salt, >=90% (TLC) |
| Hydrocortisone 21-hemisuccinate sodium salt, powder, BioReagent, suitable for cell culture |
| Hydrocortisone 21-hemisuccinate, analytical standard |
| Hydrocortisone 21-sodium succinate |
| Hydrocortisone 21-sodium succinide |
| Hydrocortisone 21-succinate |
| Hydrocortisone 21-succinate sodium salt |
| hydrocortisone hemisuccinate |
| Hydrocortisone Hemisuccinate (anhydrous) |
| Hydrocortisone hemisuccinate anhydrous |
| Hydrocortisone hemisuccinate sodium salt |
| Hydrocortisone hydrogen succinate |
| Hydrocortisone hydrogen succinate, European Pharmacopoeia (EP) Reference Standard |
| Hydrocortisone Leurquin |
| Hydrocortisone Roussel |
| Hydrocortisone sodium 21-hemisuccinate |
| Hydrocortisone sodium hemisuccinate |
| Hydrocortisone sodium succinate (JP17/USP) |
| Hydrocortisone sodium succinate [USP:BAN:JAN] |
| Hydrocortisone succinate |
| Hydrocortisone succinate (JP17) |
| Hydrocortisone succinate,sodium salt |
| Hydrocortisone-21-hemisuccinate sodium |
| Hydrocortisone-21-hemisuccinate sodium salt |
| Hydrocortisone21-hemisuccinate |
| Hydrocortisonum Hemisuccinatum |
| Hydrokortison-21-Hemisuccinat |
| Idrocortisone B. I. L. |
| IHV1VP592V |
| Intracort |
| LMST02030126 |
| Lopac0_000623 |
| LS-118633 |
| Lycortin-S |
| MFCD00069472 |
| MLS000028530 |
| MLS000069545 |
| MLS001146928 |
| MLS002207249 |
| MolPort-002-528-277 |
| MolPort-003-941-625 |
| MolPort-023-278-236 |
| NC00567 |
| NCGC00022248-03 |
| NCGC00022248-04 |
| Nordicort |
| Nositrol |
| NSC 9152 |
| NSC-7576 |
| NSC9152 |
| Opera_ID_1732 |
| Oralsome |
| Oralsone |
| PL000417 |
| PL043607 |
| Preg-4-ene-3,20-dione, 21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-, (11-beta)- |
| Pregn-4-ene-3, 21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-, monosodium salt, (11.beta.)- |
| Pregn-4-ene-3,20-dione, 21-(3-carboxy-1-oxopropoxy)-11, 17-dihydroxy- |
| Pregn-4-ene-3,20-dione, 21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-, monosodium salt, (11beta)- |
| Rapicort |
| SAM002564213 |
| Saxizon |
| SCHEMBL1320103 |
| SCHEMBL7664 |
| SCHEMBL93508 |
| SMR000058328 |
| SMR000058768 |
| Sodium 17-hydroxycorticosterone 21-succinate |
| SODIUM 4-{2-[(1S,2R,10S,11S,14R,15S,17S)-14,17-DIHYDROXY-2,15-DIMETHYL-5-OXOTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADEC-6-EN-14-YL]-2-OXOETHOXY}-4-OXOBUTANOATE |
| Sodium hydrocortisone 21-hemisuccinate |
| Sodium hydrocortisone 21-succinate |
| Sodium hydrocortisone succinate |
| sodium;4-[2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-4-oxobutanoate |
| Solu-Cortef |
| Solu-cortef (TN) |
| Solu-Glyc |
| Solu-Hizon |
| Solucortef |
| SR-01000075905 |
| SR-01000075905-1 |
| ST075193 |
| ST51037292 |
| ST51037298 |
| Succinic acid hydrocortisone |
| Succinic acid hydrocortisone sodium |
| Tox21_113501 |
| Tox21_113501_1 |
| U 4905 |
| UNII-50LQB69S1Z |
| UNII-IHV1VP592V |
| V.I.U. Intracort |
| W-107508 |
| ZINC4097472 |
US Patents and Regulatory Information for hydrocortisone sodium succinate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abraxis Pharm | HYDROCORTISONE SODIUM SUCCINATE | hydrocortisone sodium succinate | INJECTABLE;INJECTION | 088667-001 | Jun 8, 1984 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Baxter Hlthcare | HYDROCORTISONE SODIUM SUCCINATE | hydrocortisone sodium succinate | INJECTABLE;INJECTION | 086619-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Baxter Hlthcare | HYDROCORTISONE SODIUM SUCCINATE | hydrocortisone sodium succinate | INJECTABLE;INJECTION | 087567-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Abraxis Pharm | HYDROCORTISONE SODIUM SUCCINATE | hydrocortisone sodium succinate | INJECTABLE;INJECTION | 088712-001 | Jun 8, 1984 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Intl Medication | HYDROCORTISONE SODIUM SUCCINATE | hydrocortisone sodium succinate | INJECTABLE;INJECTION | 087532-001 | Mar 19, 1982 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Abbott | A-HYDROCORT | hydrocortisone sodium succinate | INJECTABLE;INJECTION | 089577-001 | Apr 11, 1989 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Abbott | A-HYDROCORT | hydrocortisone sodium succinate | INJECTABLE;INJECTION | 089578-001 | Apr 11, 1989 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Follow DrugPatentWatch: